IO Skids on Q3 Figures
IO Biotech (NASDAQ: IOBT) reported Q3 2025 financial results and business highlights. The IOB-013 study missed statistical significance on the primary PFS endpoint but supported the mechanism of action of their cancer vaccines. The company plans to discuss the next Phase 3 study for Cylembio with the FDA in December. IOBT shares fell 2.8% to 79 cents.
IO Biotech (NASDAQ: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today reported financial results for the third quarter of 2025 and recent business highlights.
“We remain keenly focused on our mission to develop novel, immune-modulatory, off-the-shelf cancer therapies for the treatment of multiple types of tumors including melanoma, lung, and head and neck cancer,” said CEO Mai-Britt Zocca.
“Although the IOB-013 study narrowly missed statistical significance on the primary PFS endpoint, the results of the study support the mechanism of action of our therapeutic cancer vaccines and, we believe, have significantly de-risked the program. We look forward to discussing the next Phase 3 study design for Cylembio with the FDA in December and remain committed to bringing Cylembio to cancer patients seeking alternative treatment options as quickly as possible.”
IOBT shares docked two cents, or 2.8%, to 79 cents.
